H.C.G (Human Chorionic Gonadotropin) versus Magnesium sulphate in suppression of preterm labour

  • Dr Prakriti Goswami Senior Resident, Department of Obstetrics & Gynaecology, G.R.M.C., Gwalior, MP, India
  • Dr Veena Agrawal Ex Professor HOD, Department of Obstetrics & Gynaecology, G.R.M.C., Gwalior, MP, India
Keywords: Human chorionic gonadotropin, Magnesium Sulphate, Preterm Labour, Tocolytic

Abstract

Introduction: Preterm labour is a major healthcare problem throughout the world, it is a major cause of perinatal mortality and morbidity.

Methods: Prospective comparative study conducted in the Department of Obstetrics & Gynaecology at Kamla Raja Hospital, Gwalior, M.P, from August 2011 to September 2012. Sample Size: 80. 50 patients were given H.C.G. and 30 were given Magnesium sulphate to suppress preterm labour. Statistical analysis done using Chi square test in SPSS software and p value < 0.05 was considered significant.

Results: Mean duration between initiation of treatment & suppression of contractions was 3.1 hrs & 2.9 hrs in women receiving H.C.G. & Magnesium sulphate respectively (p value<0.0001). Mean prolongation of pregnancy was 31.4 days and 30.33 days in women receiving H.C.G. & Magnesium sulphate respectively (p value = 0.78). Average rate of labour within 48 hrs after beginning of treatment was 8% and 6.67%, in H.C.G. & Magnesium sulphate grp respectively, p value=0.43. None of the women receiving H.C.G. had any side effects, all 30 women receiving Magnesium sulphate had minor maternal side effects, p value (<0.0001). Mean birth weight was 2.35 kgs and 2.19 kgs respectively in women receiving H.C.G. and Magnesium sulphate reapectively, (p value = 0.22).

Conclusion: Magnesium sulphate is better tocolytic drug, showing statistically significant lesser time between the initiation of treatment & suppression of contractions, as compared to H.C.G. Women receiving Magnesium sulphate suffered from minor side effects; however those treated with H.C.G. had no complaints.

Downloads

Download data is not yet available.

References

1. Cunningham FG, Gant NF, Leveno KJ, Glisterap LC. Williams Obstetrics. 22nd Ed, New York: McGraw– Hill, 2005, p. 856-8.

2. Lockwood CJ. Calcium- channel blockers in the management of preterm labor. The Lancet 1997;350(9088);1339-1340. [PubMed]

3. Ticconi C, Piccione E, Belmonte A, Rao ChV. HCG- A new kid on the block in prematurity prevention. J Matern Fetal Neonatal Med 2006 Nov;19(11):687-92. [PubMed]

4. Slattery MM, Brennan C, O´Leary MJ, Morrison JJ. Human chorionic gonadotropin inhibition of pregnant human myometrial contractility. Br J Obstet Gynecol 2001 Jul;108(7):704-8. [PubMed]

5. Reshef F, Lei ZM, Rao Chv, Pridham DD, et al. The presence of gonadotropin receptors in non–Pregnant human uterus, human placenta, fetal membranes and deciduas. J Clin Endocrinol Metab 1999;70:421– 429. [PubMed]

6. Chegini M, Lei ZM, Rao CV, Hansel W. Cellular distribution and cycle phase dependency of gonadotropin and eicosanoid binding sites in bovine corpora lutea. Biol Repord 1991;45:506–13.

7. Edelstam G, Karlsson, C, Westgren M, Lowbeer C, Swahn ML. Human chorionic gonadotropin (hCG) during third trimester pregnancy. Scand J Clin Lab Invest 2007; 67(5):519-52. [PubMed]

8. Kathleen Parfitt, BSc, RF Pharma S, Martinadale. The complete drug Reference, 32 Ed. 1999; Part 1, 1-1539.

9. Bennett P, Edwards D, Use of magnesium sulphate in obstetrics. The Lancet 1997;350:1494.

10. Esmailpoor N, Shokrieh R. Magnesium Sulfate versus Placebo in treatment of preterm labor. J Medical Science of Gilan university, Iran 2001; 39:72-77.

11. Kathleen P, Martindale W. The complete drug reference 32th Ed, Binghamton: pharmaceutical Press; 1999: 893.

12. Elliott JP. Magnesium sulphate as a tocolytic agent. Am J Obst & Gynae 1983;142;277.

13. Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev. 2009 Jan;(1):CD004661.

14. Royal college of Obst & Gyn. Magnesium sulphate to prevent cerebral palsy following preterm birth, Scientific Advisory Committee Opinion Paper 29. London: RCOG Press; 2011.

15. Reshef F, Lei ZM, Rao Chv, Pridham DD, Chegini N, Luborsky JL. The presence of gonadotropin receptors in non–Pregnant human uterus, human placenta, fetal membranes and deciduas. J Clin Endocrinol Metab 1999;70:421– 309.

16. Toth P, Gimes G, Paulin F, Rao Ch V. HCG treatment in early gestation: its impact on uterine blood flow and pregnancy outcome. Fertil Steril 1998;70:s46.

17. Kurtzman JT, Spinnato JA, Goldsmith LJ, Zimmerman MJ, Klem M, Lei ZM, Rao CV. Human chorionic gonadotropin exhibits potent inhibition of preterm delivery in a small animal model. Am J Obstet Gynecol 1999;181:853-57.

18. Ali AFM, Fateen B, Ezzet A, Badawy H, Ramaan A, El-tobge A. Treatment of preterm labour with humanchorionic gonadotropin: anewmodality. BJOG 2000 Apr;95(4):S61.

19. Al-Saffar IY, Salih HI. Human chorionic gonadotropin in treatment of preterm labour. The Iraqi Postgraduate Medical Journal 2010;9(3): 288-292.

20. Sakhavar N, Mirteimoori M, Teimoori B. Magnesium Sulfate versus HCG (Human Chorionic Gonadotropin) in Suppression of Preterm Labor. Shiraz E-Medical Journal 2008 Jul;9(3):134-140.

21. Lorzadeh N, Kazemirad S, Lorzadrh M, Dehnori A. A comparison of human chorionic gonadotropin with Magnesium Sulphate in inhibition of preterm labour. J Med Sci 2007 May;7(4):640-644.
CITATION
DOI: 10.17511/ijmrr.2015.i9.181
Published: 2015-10-31
How to Cite
1.
Goswami P, Agrawal V. H.C.G (Human Chorionic Gonadotropin) versus Magnesium sulphate in suppression of preterm labour. Int J Med Res Rev [Internet]. 2015Oct.31 [cited 2024May8];3(9):975-82. Available from: https://ijmrr.medresearch.in/index.php/ijmrr/article/view/354
Section
Original Article